AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 28 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Mice vaccinated with allogeneic fibroblasts that secrete interleukin 2 are less likely to develop metastatic brain tumors arising from breast cancer.
Because brain tumors develop in 15%-30% of patients with breast cancer, and are associated with high mortality despite the surgery-radiation-chemo armamentarium, P. Deshmukh and colleagues sought to develop a vaccine intervention.
"This study was designed to determine if an intracerebrally metastasizing breast tumor could be treated successfully with a cellular vaccine consisting of allogeneic fibroblasts (H-2(K)) modified to secrete interleukin (IL)-2," reported Deshmukh et al.
The authors measured lethal potential of spontaneously arising EO771 breast cancer cells injected into the frontal lobes of mice. Animals receiving 10(4) cells all died within 41 days. The researchers then administered a dose of 5x10(4) EO771 breast cancer cells into mice that had been vaccinated with 10(6) allogeneic fibroblasts genetically engineered to secrete IL-2.
Testing by enzyme-linked immunosorbent assay (ELISA) showed that the fibroblasts produced large quantities of IL-2, reported Deshmukh et al. ("Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice," Journal of Neurosurgery, 2001;94(2):287-292).
IL-2-vaccinated mice showed prolonged survival compared to controls that ...
Source: HighBeam Research, Cytokine-Secreting Vaccine Stops Metastatic Brain Tumors In...